| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1458789 | Inhibition of MET/SMO V404M mutant in gefitinib resistant human HCC827 cells assessed as decrease in vimentin expression at 0.05 to 0.1 uM after 72 hrs by Western blotting method | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID331966 | Half life in Sprague-Dawley rat at 2.5 mg/kg, iv | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID1458765 | Displacement of [3H]-cyclopamine from SMO V404M mutant in gefitinib resistant human HCC827 cells by scintillation counting | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID1458764 | Displacement of [3H]-cyclopamine from human wild-type SMO receptor expressed in HEK293T cell membranes by liquid scintillation spectrometry | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID438001 | Inhibition of GST-tagged c-Met expressed in Sf9 cells | 2009 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
| N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. |
| AID331997 | Inhibition of TrkA at 100 nM | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID1458777 | Inhibition of SMO V404M mutant in gefitinib resistant human HCC827 cells assessed as decrease in GLI1 activity by GLI1 luciferase reporter assay | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID331978 | AUC in Beagle dog at 5 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331962 | Inhibition of GST tagged c-Met expressed in Sf9 cells | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331976 | Tmax in Beagle dog at 5 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331965 | Solubility of compound | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331990 | Inhibition of VEGFR1 at 100 nM | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID332000 | Inhibition of GSK3-beta at 100 nM | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331999 | Inhibition of EGFR at 100 nM | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331989 | Inhibition of CYP3A4 at 10 uM | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331974 | Clearance in Beagle dog at 0.8 mg/kg, iv or 5 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331977 | Cmax in Beagle dog at 5 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331985 | Antitumor activity in human DU145 cells xenografted mouse assessed as tumor growth inhibition at 20 mg/kg, po once daily after 11 days | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331986 | Antitumor activity in human HCT116 cells xenografted mouse assessed as tumor growth inhibition at 20 mg/kg, po once daily after 14 days | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID1458766 | Antiproliferative activity against gefitinib resistant EGFR-mutated human HCC827 cells after 72 hrs by MTT assay | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID331971 | AUC in Sprague-Dawley rat at 5 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331973 | Half life in Beagle dog at 0.8 mg/kg, iv | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID1458781 | Effect on total MAPK levels in gefitinib resistant human HCC827 cells at 0.05 to 0.1 uM after 72 hrs by Western blotting method | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID1458792 | Antitumor activity against gefitinib resistant human HCC827 cells xenografted in balb/c athymic nu/nu mouse assessed as decrease in tumor size at 15 mg/kg/day, po in presence of gefitinib | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID1458783 | Effect on total AKT levels in gefitinib resistant human HCC827 cells at 0.05 to 0.1 uM after 72 hrs by Western blotting method | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID1458768 | Induction of apoptosis in gefitinib resistant human HCC827 cells at 0.5 uM after 72 hrs by annexin V-FITC-propidium iodide staining-based flow cytometry method relative to control | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID331996 | Inhibition of Abl at 100 nM | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331991 | Inhibition of VEGFR3 at 100 nM | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID418605 | Inhibition of GST-fused recombinant c-Met catalytic domain expressed in baculovirus-infected Trichoplusia ni Hi5 cells after 30 mins by DELFIA assay | 2009 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
| N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. |
| AID331995 | Inhibition of c-Kit at 100 nM | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID1458773 | Antitumor activity against gefitinib resistant human HCC827 cells xenografted in balb/c athymic nu/nu mouse assessed as decrease in tumor size at 15 mg/kg/day, po | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID1458774 | Inhibition of MET phosphorylation at Tyr1234/1235 in gefitinib resistant human HCC827 cells at 0.05 to 0.1 uM after 72 hrs by Western blotting method | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID1458770 | Inhibition of SMO V404M mutant in gefitinib resistant human HCC827 cells assessed as decrease in GLI1 activity at 60 uM by GLI1 luciferase reporter assay relative to control | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID331987 | Antitumor activity in human MNNGHOS cells xenografted mouse assessed as tumor growth inhibition at 20 mg/kg, po once daily after 26 days | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID332001 | Inhibition of IGF1R at 100 nM | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331994 | Inhibition of Flt3 at 100 nM | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331979 | Oral bioavailability in Beagle dog at 5 mg/kg | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID1458769 | Inhibition of SMO V404M mutant in gefitinib resistant human HCC827 cells assessed as decrease in GLI1 activity at 2 uM by GLI1 luciferase reporter assay relative to control | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID331964 | Inhibition of TPR-Met fusion protein assessed as Y1230-34-35 phosphorylation | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID418600 | Half life in rat at 2.17 to 2.86 mg/kg, iv | 2009 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
| N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. |
| AID331968 | Volume of distribution at steady state in Sprague-Dawley rat | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331982 | Inhibition of human VEGFR2-dependent ERK phosphorylation in HUVEC | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID332004 | Inhibition of JNK1-alpha-1 at 100 nM | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331983 | Inhibition of human VEGFR2-dependent HUVEC proliferation | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID1458787 | Inhibition of MET in gefitinib resistant human HCC827 cells assessed as decrease in MAPK44/42 phosphorylation at Thr202/Tyr204 at 0.05 to 0.1 uM after 72 hrs by Western blotting method | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID1458772 | Plasma concentration in balb/c athymic nu/nu mouse at 20 mg/kg, po measured after 5 hrs | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID331984 | Antitumor activity in human Colo205 cells xenografted mouse assessed as tumor growth inhibition at 20 mg/kg, po once daily after 16 days | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331993 | Inhibition of Tie2 at 100 nM | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID1458767 | Induction of apoptosis in gefitinib resistant human HCC827 cells at 0.1 uM after 72 hrs by annexin V-FITC-propidium iodide staining-based flow cytometry method relative to control | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID331970 | Cmax in Sprague-Dawley rat at 5 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID438002 | Inhibition of GST-tagged VEGFR expressed in Sf9 cells | 2009 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
| N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. |
| AID418601 | Inhibition of TPR-fused Met phosphorylation expressed in human 293T cells by ELISA | 2009 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
| N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. |
| AID614836 | Inhibition of human c-MET | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
| Combined SVM-based and docking-based virtual screening for retrieving novel inhibitors of c-Met. |
| AID331963 | Inhibition of GST tagged VEGFR2 expressed in Sf9 cells | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID418603 | Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay | 2009 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
| N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. |
| AID418599 | Bioavailability in rat at 4.28 to 4.98 mg/kg, po | 2009 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
| N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. |
| AID331980 | Inhibition of c-Met dependent HGF-induced human A549 cell migration | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331992 | Inhibition of Ron at 100 nM | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID1458771 | Inhibition of SMO V404M mutant in gefitinib resistant human HCC827 cells assessed as decrease in GLI1 activity at 2 to 60 uM in presence of SMO agonist SAG by GLI1 luciferase reporter assay | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID331972 | Oral bioavailability in Sprague-Dawley rat at 5 mg/kg | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID1458794 | Antitumor activity against gefitinib resistant human HCC827 cells xenografted in balb/c athymic nu/nu mouse assessed as decrease in tumor size at 15 mg/kg/day, po in presence of osimertinib | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID331975 | Volume of distribution at steady state in Beagle dog at 0.8 mg/kg, iv or 5 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID332002 | Inhibition of IKK-beta at 100 nM | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331969 | Tmax in Sprague-Dawley rat at 5 mg/kg, po | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID1458775 | Downregulation of SMO expression in gefitinib resistant human HCC827 cells at 0.05 to 0.1 uM after 72 hrs by Western blotting method | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID331998 | Inhibition of CHK1 at 100 nM | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331981 | Inhibition of c-Met dependent HGF-induced human DU145 cell scattering | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331988 | Antitumor activity in human MKN45 cells xenografted mouse assessed as tumor growth inhibition at 20 mg/kg, po once daily after 13 days | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID1458788 | Inhibition of MET in gefitinib resistant human HCC827 cells assessed as decrease in AKT phosphorylation at Ser473 at 0.05 to 0.1 uM after 72 hrs by Western blotting method | 2017 | Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
| Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. |
| AID332003 | Inhibition of JAK2 at 100 nM | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID331967 | Clearance in Sprague-Dawley rat | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1798438 | In Vitro Kinase Assay from Article 10.1016/j.bmcl.2008.04.009: \\Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.\\ | 2008 | Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
| Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |